Azeliragon by Cantex Pharmaceuticals for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Azeliragon is under clinical development by Cantex Pharmaceuticals and currently in Phase III for Coronavirus Disease 2019 (COVID-19).
Cantex Mine Development Corp. (TSXV: CD) (OTCQB: CTXDF) (the "Company") is pleased to announce that, further to its news release earlier today, it has received approval from the TSX Venture Exchange ...
WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life ...
Detailed price information for Cantex Mine Development Corp (CD-X) from The Globe and Mail including charting and trades.
Cantex's azeliragon is a well-tolerated compound, administered orally once-a-day, that inhibits the receptor for advanced glycation end products (known as RAGE). The binding of RAGE on cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results